Pfizer Enterprise Value over EBITDA Trend from 2010 to 2022

PFE
 Stock
  

USD 49.86  0.11  0.22%   

Pfizer Enterprise Value over EBITDA is increasing over the years with slightly volatile fluctuation. Ongoing Enterprise Value over EBITDA is projected to grow to 13.91 this year. During the period from 2010 to 2022 Pfizer Enterprise Value over EBITDA anual values regression line had geometric mean of 12.14 and mean square error of  8.38. Pfizer Cost of Revenue is projected to decrease significantly based on the last few years of reporting. The past year's Cost of Revenue was at 9.2 Billion. The current year Gross Profit is expected to grow to about 37.7 B, whereas Earning Before Interest and Taxes EBIT is forecasted to decline to about 18.5 B.
  
Check Pfizer financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pfizer main balance sheet or income statement drivers, such as Direct Expenses of 33.3 B, Consolidated Income of 17 B or Cost of Revenue of 9.4 B, as well as many exotic indicators such as Interest Coverage of 15.54, Long Term Debt to Equity of 0.45 or Calculated Tax Rate of 9.19. Pfizer financial statements analysis is a perfect complement when working with Pfizer Valuation or Volatility modules. It can also supplement Pfizer's financial leverage analysis and stock options assessment as well as various Pfizer Technical models . Please check the analysis of Pfizer Correlation against competitors.

Pfizer Enterprise Value over EBITDA Breakdown

Showing smoothed Enterprise Value over EBITDA of Pfizer Inc with missing and latest data points interpolated. Measures the ratio between [EV] and [EBITDAUSD].Pfizer's Enterprise Value over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pfizer's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value over EBITDA10 Years Trend
Increasing
Slightly volatile
   Enterprise Value over EBITDA   
Share
       Timeline  

Pfizer Enterprise Value over EBITDA Regression Statistics

Arithmetic Mean 12.50
Geometric Mean 12.14
Coefficient Of Variation 24.26
Mean Deviation 2.42
Median 12.96
Standard Deviation 3.03
Sample Variance 9.20
Range 9.84
R-Value 0.41
Mean Square Error 8.38
R-Squared 0.17
Significance 0.17
Slope 0.32
Total Sum of Squares 110.45

Pfizer Enterprise Value over EBITDA History

2011 8.99
2012 8.96
2013 7.12
2014 12.98
2015 16.66
2016 16.96
2017 13.88
2018 15.89
2019 11.27
2021 12.96
2022 13.91

About Pfizer Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Pfizer income statement, its balance sheet, and the statement of cash flows. Pfizer investors use historical funamental indicators, such as Pfizer's Enterprise Value over EBITDA, to determine how well the company is positioned to perform in the future. Although Pfizer investors may use each financial statement separately, they are all related. The changes in Pfizer's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Pfizer's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Pfizer Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Pfizer. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Enterprise Value over EBITDA 12.96  13.91 
Enterprise Value306.7 B295 B
Tangible Asset Value66.1 B70 B
Earnings Before Interest Taxes and Depreciation Amortization EBITDA29.3 B23.1 B
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 79000 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Pfizer without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Focused Opportunities Now

   

Focused Opportunities

Build portfolios using our predefined set of ideas and optimize them against your investing preferences
All  Next Launch Module

Currently Active Assets on Macroaxis

Please check the analysis of Pfizer Correlation against competitors. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Complementary Tools for Pfizer Stock analysis

When running Pfizer Inc price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.77
Market Capitalization
278.3 B
Quarterly Revenue Growth YOY
0.47
Return On Assets
0.13
Return On Equity
0.37
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine Pfizer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.